Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine

Transplantation

Volumn 73, Issue 12, 2002, Pages 1962-1964

  Vlahakos, D V ^a,b   Manginas, A ^b   Chilidou, D ^b   Zamanika, C ^b   Alivizatos, P A ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 3A4; ERYTHROMYCIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ITRACONAZOLE; KETOCONAZOLE; LISINOPRIL; MIBEFRADIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEFAZODONE; PREDNISONE; SIMVASTATIN; THYROID HORMONE; WARFARIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CASE REPORT; CORONARY ARTERY DISEASE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; LABORATORY TEST; LIVER TOXICITY; MALE; PRIORITY JOURNAL; RHABDOMYOLYSIS;

EID: 0037182837     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200206270-00022     Document Type: Article

References (10)

1. Safety of low-density lipoprotein cholesterol reduction with atorvastatin vs. simvastatin in a coronary heart disease population (the TARGET TANGIBLE Trial)
2. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
3. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation
4. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
5. Rhabdomyolysis induced by simvastatin and ketoconazole treatment
6. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole
7. Rhabdomyolysis in patients treated with simvastatin and cyclosporin: The role of the hepatic cytochrome P450 enzyme system activity
8. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporin
9. Simvastatin but not pravastatin is very susceptible to interact with the CYP3A4 inhibitor itraconazole
10. Rhabdomyolysis and myohemoglobinuric acute renal failure